Skip to main content
AIMN:ATLAS PHASE 2
SCHEDULED REFRESH
3 sources connected
Indication
Intelligence Summary
64
Entities Mapped
481
Archived Signals
curated archive · scheduled refresh
Phase III Live
ClinicalTrials.gov
3
Fast Corridors
SFDA · UAE · SGP
Intelligence Sources full view →
AIMN Signal Archive
481 curated events · subset of the 9,270-signal corpus
OpenFDA API
connector ready
ClinicalTrials.gov
connector ready
AIMN:SCOUT
In Dev
AIMN:SYNAPSE
In Dev
AIMN:PULSE
In Dev
Regulatory Velocity Index (?)
Signal Feed ↓ Export
Curated archive · loading
Entity
Big Pharma
Biotech
MedTech
Emerging
Indication
All
Wound Care
Diabetes
Oncology
Cardiovascular
Renal
Metabolic
Reg Heat
Accelerating
Moderate
High Friction
Pipeline4,847
Phase III329
SFDA Velocity+34% QoQ
Patent Cliffs17 assets
Archive Signals481
Clock
AIMN:ATLAS PHASE 2 · AimwellBio Intelligence · aimwellbio.com/atlas
⬡ Superbrain Architecture
Intelligence Flow
AIMN Archive → OpenFDA → ClinicalTrials.gov
↓ ↓ ↓
AIMN Superbrain
↓
AIMN:ATLAS Visualization
────────────────────────
AIMN:SCOUT → AIMN:SYNAPSE → AIMN:PULSE
Phase 3, autonomous research + regulatory forecasting
Connected Data Sources
AIMN Signal Archive
481 curated archived signals from Jan 1, Apr 14 2026. Regulatory, clinical, competitive, patent. Quadrant-classified with confidence scoring. Same domain, no latency.
481 archived signals · Jan 1, Apr 14 2026
OpenFDA Drug Database
FDA drug approvals, submissions, and application data. Public API, no auth. Surfaces NDA/BLA submissions, approval actions, PDUFA dates.
Connected · scheduled NDA/BLA refresh
ClinicalTrials.gov v2 API
Active Phase III oncology trials globally. Sponsor identification links directly to Atlas entity graph. Enrollment status, start dates, conditions.
Connected · active Phase III trials
Phase 3, Autonomous Intelligence
AIMN:SCOUT
Proprietary autonomous research layer. Multi-step intelligence gathering across PubMed, ClinicalTrials.gov, openFDA, SEC filings, and FHIN signals. Produces structured company and pipeline dossiers on demand.
In Dev, replaces static COMPANIES array with live SCOUT output
AIMN:SYNAPSE
Proprietary multi-agent coordination layer. Routes SCOUT outputs to Superbrain, schedules PULSE prediction runs, manages shared memory state, RAG integration across all connected sources.
In Dev, orchestration layer, replaces manual pipeline
AIMN:PULSE
Proprietary regulatory forecasting engine. Ingests AIMN signals and velocity data, simulates the regulatory environment forward 90 days using confidence-weighted consensus modeling. Powers the Prediction Mode heat map overlay.
Phase 3, activates Prediction Mode toggle in Atlas
Build Roadmap
DONE
Phase 1, Static Atlas: seeded entities, regulatory heat zones, share mechanic
ACTIVE
Phase 2, Scheduled data: AIMN archive, OpenFDA, ClinicalTrials.gov, signal filtering, search, Superbrain status
◈AIMN:SCOUT
◈
No Entity Selected
Select an entity on the map to begin an intelligence scan
Click any company marker
AIMN:ATLAS, How It Works
Global Regulatory Terrain at a Glance

AIMN:ATLAS maps the global biopharma regulatory landscape: thousands of companies and entities positioned at their operational headquarters, overlaid with 11 heat zones showing current approval velocity at every major drug agency, from FDA and EMA to SFDA and PMDA.

Zone color intensity reflects each agency's current score: how fast approvals are moving, how many active reviews are in flight, and where signals are clustering. The signal feed on the right is compiled on a scheduled refresh from three independent sources, AIMN Archive, OpenFDA, and ClinicalTrials.gov, surfacing NDA filings, BLA submissions, PDUFA date shifts, and Phase III enrollment events.

This is not a dashboard of curated summaries. It is the underlying signal layer.

  • ⌕Search, type any company name in the search bar and the map flies to that company's marker instantly.
  • ◈Filter chips, click BigPharma / Biotech / MedTech / Emerging to isolate entities by category on the map.
  • ●Company marker, click any marker to open the AIMN:SCOUT panel with pipeline breakdown, signal summary, and dossier generation.
  • ⇔Compare Mode, activate Compare and click two markers for a side-by-side view of pipeline stage, Phase III status, and active signals.
  • ◉Regulatory zone, click any heat zone ring to filter the signal feed to that agency's current activity.
  • ▶Signal click, click any item in the signal feed and the map pans to the corresponding regulatory zone.
  • ◎AIMN:PULSE, toggle the Pulse button to activate a 90-day forecast overlay with projected score changes per zone.
  • ⊕Clusters, zoom out and nearby companies group automatically; zoom in to resolve individual markers.
AIMN Archive
What it isAIMN's proprietary curated signal archive, 481 archived regulatory events manually reviewed and classified
SurfacesNDA/BLA submissions, approval decisions, clinical holds, PDUFA dates, agency correspondence, each tagged with confidence score
UpdatesCurated on a scheduled refresh as events are confirmed
OpenFDA Live API
What it isDirect query against FDA's public drug event and approval database via the OpenFDA REST API
SurfacesDrug application status updates, enforcement actions, adverse event filings, approval and rejection records
UpdatesPulled live on each session load, reflects current FDA database state at query time
ClinicalTrials.gov v2 API
What it isLive query against the NIH ClinicalTrials.gov registry, authoritative source for interventional study records globally
SurfacesPhase III enrollment status, study start/completion dates, protocol amendments, trial site activations for tracked companies
UpdatesPulled live on session load, reflects registrant-submitted status at query time

AIMN:ATLAS is built for professionals who need to move intelligence, not just consume it. Every mechanism below is designed to make it easy to hand off a signal, share a regulatory moment with your team, or document a finding worth tracking.

🖼
Intelligence Cards
Capture button → downloads the current map view as a formatted PNG intelligence card. Includes visible heat zones, active filters, and a timestamp. Share directly to X, LinkedIn, Facebook, or Reddit from the Capture panel, or save locally. Use this when a zone shift or approval cluster is worth flagging to your network.
⬇
Signal Export
Export button → downloads all signals currently visible in the signal feed as a structured CSV. Includes signal type, company, regulatory zone, source, date, and confidence score. Use for internal briefings, regulatory committee prep, or loading into your own analysis environment.
🔗
Direct URL
aimwellbio.com/atlas is a permanent, shareable link. The map loads current data on every session, so whoever you send it to sees the latest indexed snapshot, not a frozen image. Use this when you want a colleague, investor, or counterpart to see what the regulatory terrain looks like right now.

Intelligence is only useful when it moves. These tools exist so that what you see on ATLAS doesn't stay in your browser tab.

Scheduled Intelligence Layer

Open Console ↗
▸ The question worth surfacing

How would your platform's intelligence layer change if it could embed an adversarially-validated signal feed instead of raw public-data pulls?

Want to read the Atlas without API access? Observer is free for credentialed pros →

+ Bonus Stack Included

Plus: Atlas API Sandbox includes structured Signal endpoints + Shield source-risk endpoints + confidence labels, not just raw FDA/PubMed/ClinicalTrials pulls.

Not ready to commit? Start with this.

A 30-minute review of one brief, memo, or claim of your choosing.

Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.

Request Review →
▸ The Question Worth Sitting With

Most atlases show what disease has done. The question worth asking is what your indication is doing right now, and whether your team is the one seeing it first.

Request Atlas API Sandbox →
▸ The Shift

Old intelligence was retrospective. AI made it fast. Verification became the missing layer.

Before AI

Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.

What AI Changed

Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.

The Missing Layer

AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.

Shield protects · Signal watches · Verdict structures · FHIN reviews · Observer monitors · Enterprise deploys
▸ AimwellBio Reference Document · Edition 01

The Biopharma AI Risk Brief.

Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.

Read the Brief →
Decision-support reference · not medical, legal, or investment advice